Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Lotte & John Hecht Memorial Foundation | OTHER |
| Lungpacer Medical Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to test the feasibility of pacing the phrenic nerve to stimulate the diaphragm in order to improve the lung function in brain dead organ donors. The main questions it aims to answer are:
Participants will have an AeroPace catheter inserted and will be paced on every breath up to the time of organ donation.
Single-center, single-arm, proof-of-concept trial. Up to twenty (20) subjects on mechanical ventilation who are determined to be brain dead and whose lungs are declined for donation based on a PaO2/FiO2 ratio < 300 mmHg will be enrolled. Subjects may also be enrolled in the study at the request of the donation team if the lungs are accepted for donation but of marginal quality. Consent from the temporary substitute decision maker (TSDM) will be obtained for (i) organ donation and (ii) for study participation.
All subjects will receive Lungpacer AeroPace Protect System catheter-based transvenous phrenic nerve stimulation (LAPS-PNS) with lung-protective mechanical ventilation and standard of care for transplant donors. Insertion of the AeroPace Catheter will be conducted as soon as possible after the determination of lung transplant ineligibility. LAPS-PNS will be titrated with the ventilator to provide a contribution to the work of breathing sufficient to retain diaphragm activation.
Measurements to determine the effects of LAPS-PNS on donor lung function and physiology will be conducted until the time of organ donation. An esophageal-gastric manometer and electrical impedance tomography (EIT) unit will be utilized, respectively, to assess transdiaphragmatic pressure and lung volume distribution. Data collected for brain dead donors admitted to the same ICU over the 2 years preceding the study start who did not qualify for lung donation will serve as an unmatched comparator group.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pacing Arm | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lungpacer AeroPace catheter and device | Device | Diaphragm neurostimulation device for phrenic nerve pacing during mechanical ventilation. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in PaO2/FiO2 ratios from baseline | PaO2/FiO2 ratio measured from arterial blood gas values. | ABG measurements will be taken every 6 hours from enrolment until study endpoint for each participant. |
| Number of safety events | Determine whether any unexpected, or device-related or procedure-related complications occur in brain dead subjects. Standardized checklists will be developed to track safety events including arrhythmia, bradycardia, discomfort, hypertension/hypotension, inappropriate stimulation, pain or discomfort, phrenic nerve damage or injury, and syncope. | Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours. |
| Measure | Description | Time Frame |
|---|---|---|
| Determine percent of eligible ventilator breaths delivered with LAPS-PNS | Eligible breaths are defined as those breaths in which PNS is not precluded by clinical care/procedures or subject transport. | Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Columbian Hospital | New Westminster | B.C. | V3L 3W7 | Canada |
IPD is unable other be shared due to data sharing agreements with study sponsor and research ethics approvals pertaining to brain dead patients
Not provided
Not provided
Not provided
Not provided
Not provided
This is a single-center, single-arm, proof-of-concept trial designed to establish the feasibility of LAPS-PNS for maintaining diaphragm activation with mechanical ventilation in donors after brain death whose lungs are ineligible for transplantation due to a PaO2/FiO2 ratio < 300 mmHg. This study will determine the number of subjects in whom LAPS-PNS can recover lung function as shown by a PaO2/FiO2 ratio > 300 mmHg by the time of organ donation.
Not provided
Not provided
Not provided
Not provided
| Change in distribution of ventilation using Electrical Impedance Tomography (EIT) |
Measured in impedance units, percentage change from baseline |
| Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours. |
| Total vasopressor use (mg/mL) during LAPS-PNS use | Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours. |
| Total fluid administration (mL/kg) during LAPS-PNS dose | Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours. |
| Change in kidney function during LAPS-PNS dose from baseline | Measures of urine output (mL/kg) and creatinine (umol/L) | Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours. |
| Average vital sign recording during LAPS-PNS dose | Collection variables include temperature (degrees celsius), heart rate (bpm), SBP/DBP, MAP, RR (breaths/min) | Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours. |